Published in Biomaterials on October 26, 2007
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A (2010) 1.84
Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine (2011) 1.72
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials (2010) 1.42
Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials (2010) 1.33
Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomedicine (2010) 1.31
New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv (2009) 1.29
Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus. Int J Nanomedicine (2010) 1.17
Introduction to metallic nanoparticles. J Pharm Bioallied Sci (2010) 1.16
Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int J Mol Sci (2012) 1.13
Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol Pharm (2010) 1.12
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro Oncol (2010) 1.11
Effect of iron oxide and gold nanoparticles on bacterial growth leading towards biological application. J Nanobiotechnology (2011) 1.07
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Theranostics with multifunctional magnetic gold nanoshells: photothermal therapy and t2* magnetic resonance imaging. Invest Radiol (2011) 1.07
Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther (2009) 1.05
Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials (2011) 1.05
Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One (2013) 1.04
Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol (2012) 1.03
Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials (2009) 1.02
Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release (2011) 1.01
One-Pot Reaction and Subsequent Annealing to Synthesis Hollow Spherical Magnetite and Maghemite Nanocages. Nanoscale Res Lett (2009) 0.98
Design maps for the hyperthermic treatment of tumors with superparamagnetic nanoparticles. PLoS One (2013) 0.98
Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. Mol Pharm (2010) 0.95
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials (2011) 0.95
Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J (2009) 0.93
Magnetic nanoparticle-based approaches to locally target therapy and enhance tissue regeneration in vivo. Nanomedicine (Lond) (2012) 0.93
Applications of molecular MRI and optical imaging in cancer. Future Med Chem (2010) 0.92
Therapeutic nanomedicine for brain cancer. Ther Deliv (2013) 0.92
A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J Control Release (2011) 0.92
Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int (2013) 0.91
A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One (2008) 0.89
The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials (2010) 0.89
Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells. ACS Chem Neurosci (2013) 0.88
Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine (2014) 0.88
Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system. Pharm Res (2013) 0.88
Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv (2013) 0.86
Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model. PLoS One (2012) 0.86
Magnetic nanoparticles in primary neural cell cultures are mainly taken up by microglia. BMC Neurosci (2012) 0.85
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma. Neuro Oncol (2013) 0.84
Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine (2014) 0.84
Design and Application of Magnetic-based Theranostic Nanoparticle Systems. Recent Pat Biomed Eng (2013) 0.83
Optimal Halbach Permanent Magnet Designs for Maximally Pulling and Pushing Nanoparticles. J Magn Magn Mater (2011) 0.83
Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier. Int J Nanomedicine (2014) 0.83
Compact zwitterion-coated iron oxide nanoparticles for in vitro and in vivo imaging. Integr Biol (Camb) (2013) 0.82
Transcellular Transport of Heparin-coated Magnetic Iron Oxide Nanoparticles (Hep-MION) Under the Influence of an Applied Magnetic Field. Pharmaceutics (2010) 0.82
Cancer targeted therapeutics: From molecules to drug delivery vehicles. J Control Release (2015) 0.82
Hierarchically-Structured Magnetic Nanoconstructs with Enhanced Relaxivity and Cooperative Tumor Accumulation. Adv Funct Mater (2014) 0.81
Triple-Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo. Theranostics (2016) 0.81
Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. Nanoscale (2015) 0.81
Potential of magnetic nanoparticles for targeted drug delivery. Nanotechnol Sci Appl (2012) 0.81
Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy. Int J Nanomedicine (2016) 0.80
Assessment of the evolution of cancer treatment therapies. Cancers (Basel) (2011) 0.80
A Review of Clinical Translation of Inorganic Nanoparticles. AAPS J (2015) 0.79
Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography. Mol Imaging Biol (2013) 0.79
Development of a novel lipophilic, magnetic nanoparticle for in vivo drug delivery. Pharmaceutics (2013) 0.79
Water-soluble L-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma. Int J Nanomedicine (2015) 0.78
Magnetic nanoparticles and nanocomposites for remote controlled therapies. J Control Release (2015) 0.78
Nanotechnology applications for glioblastoma. Neurosurg Clin N Am (2012) 0.78
Real-time monitoring of magnetic drug targeting using fibered confocal fluorescence microscopy. J Control Release (2016) 0.78
Non-covalent synthesis of metal oxide nanoparticle-heparin hybrid systems: a new approach to bioactive nanoparticles. Int J Mol Sci (2013) 0.78
Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev (2015) 0.77
Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine (Lond) (2014) 0.77
Magnetic tumor targeting of β-glucosidase immobilized iron oxide nanoparticles. Nanotechnology (2013) 0.77
Hybrid-Actuating Macrophage-Based Microrobots for Active Cancer Therapy. Sci Rep (2016) 0.77
Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci Rep (2016) 0.76
Functionalized iron oxide nanoparticles for controlling the movement of immune cells. Nanoscale (2015) 0.76
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge. Nanomaterials (Basel) (2015) 0.75
Size-dependent cytotoxicity of Fe3O4 nanoparticles induced by biphasic regulation of oxidative stress in different human hepatoma cells. Int J Nanomedicine (2016) 0.75
Size-regulated group separation of CoFe2O4 nanoparticles using centrifuge and their magnetic resonance contrast properties. Nanoscale Res Lett (2013) 0.75
Effect of micro- and nanomagnetite on printing toner properties. ScientificWorldJournal (2014) 0.75
Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. Sci Rep (2017) 0.75
Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Non-invasive administration of biodegradable nano-carrier vaccines. Am J Transl Res (2017) 0.75
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents. Int J Environ Res Public Health (2016) 0.75
Enhanced and selective delivery of enzyme therapy to 9L-glioma tumor via magnetic targeting of PEG-modified, β-glucosidase-conjugated iron oxide nanoparticles. Int J Nanomedicine (2014) 0.75
Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme. J Biomed Nanotechnol (2016) 0.75
Compensatory UTE/T2W Imaging of Inflammatory Vascular Wall in Hyperlipidemic Rabbits. PLoS One (2015) 0.75
Polymeric nanocomposites loaded with fluoridated hydroxyapatite Ln(3+) (Ln = Eu or Tb)/iron oxide for magnetic targeted cellular imaging. Cancer Biol Med (2015) 0.75
Lactoferrin conjugated iron oxide nanoparticles for targeting brain glioma cells in magnetic particle imaging. Nanoscale (2015) 0.75
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system. Beilstein J Nanotechnol (2014) 0.75
Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer. Oncotarget (2016) 0.75
Therapeutic effects of dihydroartemisinin and transferrin against glioblastoma. Nutr Res Pract (2016) 0.75
Growth factor choice is critical for successful functionalization of nanoparticles. Front Neurosci (2015) 0.75
Structural and magnetic properties of iron nanowires and iron nanoparticles fabricated through a reduction reaction. Beilstein J Nanotechnol (2015) 0.75
The application of magnetic nanoparticles for the treatment of brain tumors. Front Chem (2014) 0.75
Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging. Int J Nanomedicine (2015) 0.75
Curcumin encapsulated zeolitic imidazolate frameworks as stimuli responsive drug delivery system and their interaction with biomimetic environment. Sci Rep (2017) 0.75
The Effect of Co0.2Mn0.8Fe2O4 Ferrite Nanoparticles on the C2 Canine Mastocytoma Cell Line and Adipose-Derived Mesenchymal Stromal Stem Cells (ASCs) Cultured Under a Static Magnetic Field: Possible Implications in the Treatment of Dog Mastocytoma. Cell Mol Bioeng (2017) 0.75
Increased cellular uptake of lauryl gallate loaded in superparamagnetic poly(methyl methacrylate) nanoparticles due to surface modification with folic acid. J Mater Sci Mater Med (2016) 0.75
In Situ Atomic-Scale Probing of the Reduction Dynamics of 2-Dimensional Fe2O3 Nanostructures. ACS Nano (2016) 0.75
Phosphonomethyl iminodiacetic acid-conjugated cobalt oxide nanoparticles liberate Co(++) ion-induced stress associated activation of TNF-α/p38 MAPK/caspase 8-caspase 3 signaling in human leukemia cells. J Biol Inorg Chem (2014) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol (2001) 4.84
Locoregional cancer treatment with magnetic drug targeting. Cancer Res (2000) 3.05
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med (1994) 2.79
Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging (1995) 2.67
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res (1996) 2.35
Clinical applications of magnetic drug targeting. J Surg Res (2001) 2.25
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc Natl Acad Sci U S A (1998) 1.91
Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology (1997) 1.87
Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging (2005) 1.83
Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res (1998) 1.68
Targeted therapy for brain tumours. Nat Rev Drug Discov (2004) 1.63
Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target (2003) 1.58
Primary brain tumors: review of etiology, diagnosis and treatment. Am Fam Physician (1994) 1.53
Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res (1999) 1.48
Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg (1995) 1.36
Vascular microenvironment in gliomas. J Neurooncol (2001) 1.36
Malignant gliomas in 2005: where to GO from here? JAMA (2005) 1.36
Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release (2003) 1.34
Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc (1984) 1.25
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25
Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet (2006) 1.20
Brain tumors in children. Arch Neurol (1999) 1.18
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res (2000) 1.17
Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol (1983) 1.16
Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res (2002) 1.11
Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res (1997) 1.08
Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol (1999) 1.08
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res (1993) 1.07
Targeted drug delivery for brain cancer treatment. J Control Release (2000) 0.98
Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol (2004) 0.97
Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol (1983) 0.96
CBF and CBV measurements by USPIO bolus tracking: reproducibility and comparison with Gd-based values. J Magn Reson Imaging (1999) 0.95
Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol (2003) 0.95
Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target (1998) 0.94
Intra-arterial chemotherapy of malignant gliomas. J Neuroradiol (1988) 0.89
Noninvasive assessment of the functional neovasculature in 9L-glioma growing in rat brain by dynamic 1H magnetic resonance imaging of gadolinium uptake. J Cereb Blood Flow Metab (2000) 0.88
Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model. J Neurooncol (1992) 0.85
Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy. J Neurosurg (1977) 0.82
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol (2007) 1.86
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem (2003) 1.66
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target (2003) 1.58
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J (2006) 1.52
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials (2010) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys (2008) 1.39
Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin N Am (2009) 1.38
Real-time molecular imaging of tricarboxylic acid cycle metabolism in vivo by hyperpolarized 1-(13)C diethyl succinate. J Am Chem Soc (2011) 1.36
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res (2006) 1.34
Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials (2010) 1.33
Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res (2007) 1.31
Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release (2007) 1.29
Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of 13C imaging of atheroma in mice. NMR Biomed (2011) 1.27
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26
A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia (2008) 1.25
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging (2003) 1.25
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther (2004) 1.25
Dynamic imaging of emerging resistance during cancer therapy. Cancer Res (2006) 1.23
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23
Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. Cancer Res (2009) 1.17
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res (2007) 1.16
Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res (2003) 1.16
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas. Cancer Res (2006) 1.15
Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am (2006) 1.15
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging (2009) 1.15
Characterization of magnetite nanoparticles for SQUID-relaxometry and magnetic needle biopsy. J Magn Magn Mater (2009) 1.14
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol Pharm (2010) 1.12
Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors α. J Surg Res (2011) 1.11
Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin Cancer Res (2010) 1.10
Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging (2003) 1.10
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J (2005) 1.10
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A (2008) 1.08
Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp Biol Med (Maywood) (2009) 1.06
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol Cancer Ther (2012) 1.06
Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials (2011) 1.05
Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials (2011) 1.04
Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials (2009) 1.02
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med (2005) 1.01